4D Molecular Therapeutics 향후 성장

Future 기준 점검 2/6

4D Molecular Therapeutics 의 수익은 연간 5.1% 감소할 것으로 예상되는 반면, 연간 수익은 39.7% 로 증가할 것으로 예상됩니다. EPS는 연간 7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -76.5% 로 예상됩니다.

핵심 정보

-5.1%

이익 성장률

7.04%

EPS 성장률

Biotechs 이익 성장	23.8%
매출 성장률	39.7%
향후 자기자본이익률	-76.54%
애널리스트 커버리지	Good
마지막 업데이트	18 Dec 2025

최근 향후 성장 업데이트

Recent updates

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop

Dec 19

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 18

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Nov 24

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08

이익 및 매출 성장 예측

NasdaqGS:FDMT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	22	-203	-251	N/A	5
12/31/2026	23	-210	-237	N/A	6
12/31/2025	38	-206	-242	N/A	8
9/30/2025	0	-209	-185	-183	N/A
6/30/2025	0	-196	-170	-166	N/A
3/31/2025	0	-176	-157	-153	N/A
12/31/2024	0	-161	-138	-135	N/A
9/30/2024	0	-143	-117	-113	N/A
6/30/2024	20	-110	-87	-85	N/A
3/31/2024	20	-105	-79	-77	N/A
12/31/2023	21	-101	-79	-76	N/A
9/30/2023	22	-96	-77	-73	N/A
6/30/2023	2	-111	-98	-93	N/A
3/31/2023	2	-110	-97	-91	N/A
12/31/2022	3	-107	-98	-87	N/A
9/30/2022	2	-105	-102	-86	N/A
6/30/2022	3	-102	-97	-81	N/A
3/31/2022	17	-81	-92	-77	N/A
12/31/2021	18	-71	-78	-69	N/A
9/30/2021	17	-67	-69	-65	N/A
6/30/2021	23	-52	-64	-62	N/A
3/31/2021	12	-60	-53	-52	N/A
12/31/2020	14	-57	-52	-51	N/A
9/30/2020	17	-52	-43	-42	N/A
6/30/2020	10	-61	-42	-40	N/A
3/31/2020	8	-54	-45	-42	N/A
12/31/2019	7	-49	-40	-37	N/A
9/30/2019	9	-35	-36	-33	N/A
6/30/2019	13	-21	N/A	-27	N/A
3/31/2019	14	-15	N/A	-22	N/A
12/31/2018	14	-10	N/A	-16	N/A
12/31/2017	6	-11	N/A	8	N/A

애널리스트 향후 성장 전망

수입 대 저축률: FDMT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: FDMT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: FDMT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: FDMT 의 수익(연간 39.7%)이 US 시장(연간 10.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: FDMT 의 수익(연간 39.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: FDMT는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/29 08:38
종가	2025/12/26 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

4D Molecular Therapeutics, Inc.는 15명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Huidong Wang	Barclays
null null	BMO Capital Markets Equity Research
Konstantinos Biliouris	BMO Capital Markets Equity Research

4D Molecular Therapeutics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 18%

Price target decreased by 7.6% to US$34.18

Price target decreased by 8.7% to US$45.64

Price target increased by 9.3% to US$54.75

Consensus revenue estimates decrease by 33%, EPS upgraded

Recent updates

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop

4D Molecular Therapeutics, Inc. Announces Intention to Implement Protocol Amendments to the 4D-1 and 4FRONT-2 Phase 3 Clinical Trials of 4D-150 in Wet AMD

4D Molecular Therapeutics, Inc. Appoints Kristian Humer as Principal Financial Officer

4D Molecular Therapeutics, Inc. Appoints Kristian Humer as Chief Financial Officer

New minor risk - Shareholder dilution

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.999994 million.

Consensus revenue estimates increase by 27%

4D Molecular Therapeutics, Inc. Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

4D Molecular Therapeutics, Inc. Appoints Ashoo Gupta as Principal Accounting Officer, Effective September 30, 2025

High number of new directors

4Dmt Announces Executive Changes

4D Molecular Therapeutics Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

4D Molecular Therapeutics, Inc. Announces Workforce Reduction of Approximately 25% of Current and Planned Roles in July 2025

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell 3000 Growth Index

First quarter 2025 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics Announces RMAT Designation Granted by FDA for 4D-150 for DME

4D Molecular Therapeutics, Inc., Annual General Meeting, Jun 17, 2025

4D Molecular Therapeutics Announces First Patients Enrolled in 4Front-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet Amd

Consensus revenue estimates increase by 18%

Price target decreased by 7.6% to US$34.18

Full year 2024 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

New minor risk - Share price stability

New major risk - Revenue and earnings growth

4D Molecular Therapeutics, Inc. Announces Strategically Focused Pipeline, Updated Phase 3 4Front Program Plans

4Dmt Announces Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Price target decreased by 8.7% to US$45.64

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

New major risk - Revenue and earnings growth

New major risk - Share price stability

4D Molecular Therapeutics Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4Front Phase 3 Program At 4D-150 Wet AMD Development Day

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

4D Molecular Therapeutics, Inc. Announces Management Changes

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

4D Molecular Therapeutics, Inc. Announces Initial Interim 24-Week Data from the Population Extension Cohort of Its Phase 2 Clinical Trial

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis At 47Th European Cystic Fibrosis Conference

First quarter 2024 earnings released: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc., Annual General Meeting, May 21, 2024

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 9.3% to US$54.75

4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Consensus revenue estimates decrease by 33%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Chief Medical Officer exercised options and sold US$354k worth of stock

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $299.999626 million.

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

4D Molecular Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

New major risk - Share price stability

Price target increased by 9.6% to US$37.00

4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

Co-Founder notifies of intention to sell stock

Insufficient new directors